Based on our clinical, in vitro, and in vivo studies, this study provided evidence that CD44 promotes lung cancer metastasis through ERK/ZEB1 activation and may serve as a potential therapeutic target for lung cancer metastasis. Here, ZEB1 is linked to lung carcinoma.